Tuoxin Pharmaceutical Group Co., Ltd. Class A

Tuoxin Pharmaceutical Group Co., Ltd. Class A

SSZSE:301089
19.73
CNY
-0.42
(-2.08%)
-0.63EPS
3.10BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.24
6.38
3.93
3.12
4.11
4.14
4.1
5.57
5.05
6.22
6.63
3.39
2.99
3.36
Basic EPS, GAAP
0.3
0.25
0.2
0.06
0.35
0.67
0.65
1.19
0.66
2.27
1.93
-0.16
-0.55
-0.63
Free Cash Flow per Basic Share
-0.01
-0.69
0.11
0.4
-0.05
0.12
0.11
0.48
-0.55
0.95
-1.26
0.15
-0.56
- -
Dividend per Share
0.15
0.25
0.13
0.11
0.07
0.1
0.15
0.1
0.08
0.12
0.4
0.25
- -
- -
Book Value per Share
1.96
2.14
2.49
2.55
2.7
3.51
4.05
5.19
8.71
10.92
12.67
12.27
11.73
11.42
Tangible Book Value per Share
1.61
1.8
2.1
2.17
1.89
2.72
3.28
4.44
8.04
10.25
12.01
11.62
11.1
10.63
Basic Weighted Avg Shares
60
59
93
101
94
94
94
95
100
126
126
124
127
128
Sales/Revenue/Turnover
374
376
364
315
387
391
386
528
502
785
836
422
378
430
Operating Margin (%)
7.79
8.48
8.05
4.53
13.8
25.24
21.39
28.59
18.01
41.43
39.07
-3.3
-12.59
-12.39
Depreciation Expense
5
11
14
15
15
16
16
17
31
41
47
48
66
- -
Net Income, GAAP
18
15
19
6
33
63
61
113
66
287
243
-20
-70
-80
Effective Tax Rate (%)
18.16
30.37
17.41
29.86
20.8
18.7
12.96
16.72
15.8
11.91
23.21
- -
- -
- -
Profit Margin (%)
4.8
3.92
5.09
1.92
8.52
16.17
15.87
21.37
13.08
36.51
29.09
-4.72
-18.41
-18.73
Working Capital
17
36
53
66
38
31
-12
-6
542
590
628
512
439
406
LT Debt
- -
13
10
13
10
- -
- -
5
- -
- -
- -
3
2
1
Total Equity
185
203
235
241
255
331
383
491
1,097
1,376
1,603
1,553
1,484
1,445
Return on Invested Capital (%)
6.03
4.8
4.74
1.08
8.58
14.01
12.07
19.8
7.39
21.73
15.91
- -
- -
- -
Return on Capital (%)
9.35
7.61
7.89
3.64
15.18
21.25
23.16
24.77
8.05
22.42
16.12
- -
- -
- -
Return on Common Equity (%)
10.14
7.59
8.46
2.54
13.29
21.57
17.15
25.81
8.27
23.17
16.32
-1.26
-4.59
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
127
127
127
Market Capitalization
3,534
2,584
3,100

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
580
556
544
Cash, Cash Equivalents & STI
231
205
192
Accounts Receivable, Net
45
60
62
Inventories
196
205
205
Total Current Liabilities
141
140
139
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.98%
31.58%
-4.4%
Free Cash Flow
-119.96%
-271.93%
-476.63%
Net Income, GAAP
97.18%
84.25%
250.32%
Sales/Revenue/Turnover
4.4%
-0.4%
-10.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
108
110
107
96
422
2025
97
85
- -
107
378
2026
93
119
111
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
-0.03
-0.01
-0.14
-0.16
2025
-0.03
-0.12
- -
-0.31
-0.55
2026
-0.08
-0.14
-0.1
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.25
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Shao Hua Yang
Full Time Employees
1,543
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Xinxiang China
IPO Date
Oct 27, 2021
Business
Tuoxin Pharmaceutical Group Co., Ltd. is a China-based biopharmaceutical company engaged in the research, development, manufacturing, and distribution of nucleoside and nucleotide active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and functional biochemical products. The company's product portfolio is organized into pyrimidine series, including cytosine, cytidine, 5-fluorocytosine (flucytosine), and 5-fluorocytidine; purine series, encompassing inosine, adenosine, acyclovir, and related derivatives; and nucleoside and nucleotide series, which feature citicoline sodium, ribavirin, uridine, cytarabine hydrochloride, and azvudine intermediates, primarily serving therapeutic applications across antiviral, antineoplastic, cardiovascular, and central nervous system indications. In addition to commercial API and intermediate supply, the company provides customized contract development and manufacturing organization (CDMO) and contract manufacturing (CMO) services, supported by proprietary technology platforms spanning efficient catalytic chemical synthesis, microbial fermentation, and semi-synthetic bioconversion. In recent operational and strategic developments, the company executed a corporate restructuring and rebranding, transitioning its corporate name from Xinxiang Tuoxin Pharmaceutical Co., Ltd. to Tuoxin Pharmaceutical Group Co., Ltd. To support capacity expansion and product diversification into non-nucleoside specialty APIs and functional health ingredients, the company established Tuoxin Pharmaceutical (Inner Mongolia) Co., Ltd. and initiated construction of a major green biomanufacturing base in the Tuoketuo Economic Development Zone, while advancing commercialization initiatives in synthetic biology products such as ergothioneine. On the collaborative research front, its subsidiary Henan Nucleoside Drug Research Institute Co., Ltd. entered into strategic research partnerships with China Pharmaceutical University and Nanjing University of Chinese Medicine to develop vincamine formulations for pulmonary fibrosis, alongside formalizing joint industry-academia innovation agreements with Xinxiang University. Founded in 2005 and headquartered in Xinxiang, Henan Province, China, the company operates principal operating subsidiaries including Xinxiang Pharmaceutical Co., Ltd., Dingxin Pharmaceutical, Jingquan Biology, and Tuoxin Pharmaceutical (Inner Mongolia) Co., Ltd., marketing its products across domestic Chinese markets as well as international destinations in Asia, Europe, and other global regions under international Good Manufacturing Practice (GMP) standards and Drug Master File (DMF) regulatory filings.